Bioxyne Ltd Signs Manufacturing Agreement with Aurora Cannabis.
Bioxyne Ltd (ASX: BXN) has entered into a major manufacturing agreement with Aurora Cannabis Inc., a global leader in the medical cannabis industry. Initially, this agreement covers the supply of GMP-certified medicinal cannabis oils to the Australian market, with initial shipments already completed. The scope will expand to include the production of cannabis vapes for distribution in Australia, the United Kingdom, and Germany.
This partnership highlights Bioxyne's growing expertise in pharmaceutical-grade cannabis manufacturing, positioning the company as a reliable supplier on the global stage. Breathe Life Sciences (BLS), Bioxyne’s wholly owned subsidiary, will manage the manufacturing of these precision-dosed products for international markets. This agreement signifies a key milestone in Bioxyne’s journey from a prominent Australian manufacturer to a globally recognized leader in the medical cannabis sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Bioxyne Ltd Signs Manufacturing Agreement with Aurora Cannabis.
Bioxyne Ltd (ASX: BXN) has entered into a major manufacturing agreement with Aurora Cannabis Inc., a global leader in the medical cannabis industry. Initially, this agreement covers the supply of GMP-certified medicinal cannabis oils to the Australian market, with initial shipments already completed. The scope will expand to include the production of cannabis vapes for distribution in Australia, the United Kingdom, and Germany.
This partnership highlights Bioxyne's growing expertise in pharmaceutical-grade cannabis manufacturing, positioning the company as a reliable supplier on the global stage. Breathe Life Sciences (BLS), Bioxyne’s wholly owned subsidiary, will manage the manufacturing of these precision-dosed products for international markets. This agreement signifies a key milestone in Bioxyne’s journey from a prominent Australian manufacturer to a globally recognized leader in the medical cannabis sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au